ATE328283T1 - Screeningverfahren und verbindungen zur behandlung von friedreich ataxia - Google Patents
Screeningverfahren und verbindungen zur behandlung von friedreich ataxiaInfo
- Publication number
- ATE328283T1 ATE328283T1 AT02014542T AT02014542T ATE328283T1 AT E328283 T1 ATE328283 T1 AT E328283T1 AT 02014542 T AT02014542 T AT 02014542T AT 02014542 T AT02014542 T AT 02014542T AT E328283 T1 ATE328283 T1 AT E328283T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- friedreich ataxia
- compounds
- screening methods
- relates
- Prior art date
Links
- 208000024412 Friedreich ataxia Diseases 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 238000012216 screening Methods 0.000 title 1
- 102000006587 Glutathione peroxidase Human genes 0.000 abstract 2
- 108700016172 Glutathione peroxidases Proteins 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 abstract 1
- 102000003869 Frataxin Human genes 0.000 abstract 1
- 108090000217 Frataxin Proteins 0.000 abstract 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229950010033 ebselen Drugs 0.000 abstract 1
- 229910052711 selenium Inorganic materials 0.000 abstract 1
- 239000011669 selenium Substances 0.000 abstract 1
- 229940091258 selenium supplement Drugs 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pyrrole Compounds (AREA)
- Processing Of Solid Wastes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02014542A EP1378753B1 (de) | 2002-07-01 | 2002-07-01 | Screeningverfahren und Verbindungen zur Behandlung von Friedreich ataxia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE328283T1 true ATE328283T1 (de) | 2006-06-15 |
Family
ID=29719694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02014542T ATE328283T1 (de) | 2002-07-01 | 2002-07-01 | Screeningverfahren und verbindungen zur behandlung von friedreich ataxia |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20050222218A1 (de) |
| EP (1) | EP1378753B1 (de) |
| AT (1) | ATE328283T1 (de) |
| CA (1) | CA2489294A1 (de) |
| DE (1) | DE60211875T2 (de) |
| WO (1) | WO2004003565A2 (de) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT500929B1 (de) * | 2004-11-09 | 2007-03-15 | Medizinische Uni Wien Muw | Pharmazeutische zubereitung die erythropoietin enthält |
| ES2714900T3 (es) | 2005-06-01 | 2019-05-30 | Bioelectron Tech Corp | Productos terapéuticos redox activos para el tratamiento de enfermedades mitocondriales y otras afecciones y modulación de biomarcadores energéticos |
| WO2007015536A1 (ja) * | 2005-08-03 | 2007-02-08 | Sumitomo Chemical Company, Limited | 化合物、光電変換素子及び光電気化学電池 |
| WO2007035496A1 (en) | 2005-09-15 | 2007-03-29 | Edison Pharmaceuticals, Inc. | Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| EP1951656B1 (de) | 2005-11-11 | 2015-08-05 | The Scripps Research Institute | Inhibitoren der histondeacetylase als therapeutika für neurologische erkrankungen |
| WO2007085036A1 (en) * | 2006-01-26 | 2007-08-02 | Medizinische Universität Wien | Treatment of friedreich' s ataxia |
| EP2617417A1 (de) | 2006-02-22 | 2013-07-24 | Edison Pharmaceuticals, Inc. | Seitenkettenvarianten von redoxaktiven Therapeutika zur Behandlung von mitochondrialen Erkrankungen und anderen Zuständen sowie Modulation von Energie-Biomarkern |
| WO2007100652A2 (en) * | 2006-02-22 | 2007-09-07 | Edison Pharmaceuticals, Inc. | Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| EP1891946A1 (de) * | 2006-08-14 | 2008-02-27 | Santhera Pharmaceuticals (Schweiz) AG | Transmukosale Verabreichung von 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinon |
| DE102006058183A1 (de) | 2006-11-29 | 2008-06-05 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Verwendung von Substanzen, die den zellulären Glutathion-Gehalt absenken, zur Herstellung eines Arzneimittels zur Behandlung von T-Zell vermittelten Autoimmunkrankheiten |
| SI3456707T1 (sl) | 2007-11-06 | 2020-10-30 | Ptc Therapeutics, Inc. | Derivati 4-(P-kuinonil)-2-hidroksibutanamida za zdravljenje mitohondrijske bolezni |
| WO2009089224A1 (en) | 2008-01-08 | 2009-07-16 | Edison Pharmaceuticals, Inc. | (HET) ARYL-p-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES |
| JP5710277B2 (ja) | 2008-03-05 | 2015-04-30 | エジソン ファーマシューティカルズ， インコーポレイテッド | 酸化ストレス疾患の処置のための２−置換−ｐ−キノン誘導体 |
| JP2011516489A (ja) | 2008-03-31 | 2011-05-26 | ユニバーシティ・オブ・サウス・フロリダ | 疾患誘発性運動失調症および非運動失調性平衡異常の治療法 |
| WO2009143019A2 (en) * | 2008-05-23 | 2009-11-26 | University Of South Florida | Method of treating peripheral nerve sensory loss using compounds having nicotinic acetylcholine receptor activity |
| JP5798481B2 (ja) | 2008-06-25 | 2015-10-21 | エジソン ファーマシューティカルズ， インコーポレイテッド | 酸化ストレス疾患を治療するための２−ヘテロシクリルアミノアルキル−（ｐ−キノン）誘導体 |
| JP2012502064A (ja) | 2008-09-10 | 2012-01-26 | エジソン ファーマシューティカルズ， インコーポレイテッド | 酸化還元活性治療剤を用いての広汎性発達障害の処置 |
| WO2010083327A2 (en) * | 2009-01-14 | 2010-07-22 | Mayo Foundation For Medical Education And Research | Measuring levels of frataxin |
| HUE037574T2 (hu) * | 2009-04-28 | 2018-09-28 | Bioelectron Tech Corp | Leber-féle örökletes optikus neuropátia és domináns optikus atrofia kezelése tokotrienol kinonokkal |
| US20100273892A1 (en) * | 2009-04-28 | 2010-10-28 | Miller Guy M | Formulations of tocotrienol quinones for the treatment of ophthalmic diseases |
| CA2797644A1 (en) | 2009-12-31 | 2011-07-07 | Edison Pharmaceuticals, Inc. | Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones |
| SI2611457T1 (sl) | 2010-08-30 | 2014-09-30 | Roberto Testi | Sestavki in postopki za zdravljenje Friedreichove ataksije z interferonom gama |
| WO2012148927A2 (en) | 2011-04-26 | 2012-11-01 | Retrotope, Inc. | Impaired energy processing disorders and mitochondrial deficiency |
| WO2012149478A2 (en) * | 2011-04-28 | 2012-11-01 | Serket Pharma, Llc | Agents useful for treating friedreich's ataxia and other neurodegenerative diseases |
| ES2795798T3 (es) | 2011-07-06 | 2020-11-24 | Ptc Therapeutics Inc | Tratamiento de aciduria metilmalónica, aciduria isovalérica, y otras acidurias orgánicas con tocotrienol quinonas |
| CA2883882A1 (en) | 2012-09-07 | 2014-03-13 | Edison Pharmaceuticals, Inc. | Benzoquinone derivatives for treating oxidative stress disorders |
| US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| US20140275045A1 (en) | 2013-03-15 | 2014-09-18 | Edison Pharmaceuticals, Inc. | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| CA2906145A1 (en) | 2013-03-15 | 2014-09-18 | Edison Pharmaceuticals, Inc. | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders |
| US9670170B2 (en) | 2013-03-15 | 2017-06-06 | Bioelectron Technology Corporation | Resorufin derivatives for treatment of oxidative stress disorders |
| US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
| CA2912871A1 (en) | 2013-05-31 | 2014-12-04 | Edison Pharmaceuticals, Inc. | Carboxylic acid derivatives for treatment of oxidative stress disorders |
| US10058542B1 (en) | 2014-09-12 | 2018-08-28 | Thioredoxin Systems Ab | Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith |
| US10442779B2 (en) | 2014-09-22 | 2019-10-15 | Fratagene Therapeutics S.R.L. | Compositions and methods for treating Friedreich's ataxia |
| WO2016100579A1 (en) | 2014-12-16 | 2016-06-23 | Edison Pharmaceuticals, Inc., | Polymorphic and amorphous forms of (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide |
| EP3389646A1 (de) | 2015-12-17 | 2018-10-24 | BioElectron Technology Corporation | Flouralkyl, flouralkoxy, phenoxy, heteroaryloxy, alkoxy und amin-1,4-benzochinon-derivate zur behandlung von oxidativen stresserkrankungen |
| US10426775B2 (en) | 2017-09-11 | 2019-10-01 | Fratagene Therapeutics Srl | Methods for treating Friedreich's ataxia with etravirine |
| FI3866772T3 (fi) | 2018-10-17 | 2024-01-11 | Ptc Therapeutics Inc | 2,3,5-trimetyyli-6-nonyylisykloheksa-2,5-dieeni-1,4-dioni alfa-synukleinopatioiden, tauopatioiden ja muiden häiriöiden estämiseen ja hoitoon |
| WO2021077034A1 (en) | 2019-10-18 | 2021-04-22 | Ptc Therapeutics, Inc. | 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating hemoglobinopathy, thalassemia, sickle cell disease and other disorders |
| EP4351545A1 (de) | 2021-06-07 | 2024-04-17 | Katholieke Universiteit Leuven | Idebenon zur behandlung von arzneimittelresistenter epilepsie |
| CN117586204A (zh) * | 2022-08-19 | 2024-02-23 | 中国人民解放军海军军医大学 | 异硒唑酮类化合物、其合成方法及用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5128365A (en) * | 1989-07-19 | 1992-07-07 | The Trustees Of Columbia University In The City Of New York | Compounds having glutathione peroxidase activity and use thereof |
| US6133322A (en) * | 1998-10-29 | 2000-10-17 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Quinone derivatives for treating or preventing diseases associated with iron overload |
-
2002
- 2002-07-01 DE DE60211875T patent/DE60211875T2/de not_active Expired - Fee Related
- 2002-07-01 AT AT02014542T patent/ATE328283T1/de not_active IP Right Cessation
- 2002-07-01 EP EP02014542A patent/EP1378753B1/de not_active Expired - Lifetime
-
2003
- 2003-07-01 US US10/519,430 patent/US20050222218A1/en not_active Abandoned
- 2003-07-01 WO PCT/EP2003/007006 patent/WO2004003565A2/en not_active Ceased
- 2003-07-01 CA CA002489294A patent/CA2489294A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE60211875D1 (de) | 2006-07-06 |
| EP1378753B1 (de) | 2006-05-31 |
| CA2489294A1 (en) | 2004-01-08 |
| DE60211875T2 (de) | 2006-10-26 |
| US20050222218A1 (en) | 2005-10-06 |
| WO2004003565A2 (en) | 2004-01-08 |
| WO2004003565A3 (en) | 2004-10-14 |
| EP1378753A1 (de) | 2004-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60211875D1 (de) | Screeningverfahren und Verbindungen zur Behandlung von Friedreich ataxia | |
| DE60323155D1 (de) | Von transthyretin und zur hemmung von transthyretin-fehlfaltung | |
| EP1302542A4 (de) | Neues, physiologisch aktives peptid und dessen verwendung | |
| EP1638443A4 (de) | Isoformen von gehirn-natriuretischem peptid | |
| DE60219917D1 (de) | Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen | |
| ATE530560T1 (de) | Vegf bindende und geträgerte peptide zur behandlung von hautkrankheiten | |
| ATE353880T1 (de) | Neue verwendung von pyrimidin- oder triazin-2- carbonsäurenitrilen zur behandlung von krankheiten, die mit cysteinproteaseaktivität assoziiert sind, und neue pyridimidin-2- carbonsäurenitrilderivate | |
| DE602004021797D1 (de) | Behandlung von alzheimer-krankheit und amyloider gehirnangiopathie | |
| ATE344317T1 (de) | Substanzen zur vorbeugung und behandlung von autoimmunkrankheiten | |
| ATE361745T1 (de) | Carbamatverbindungen zur vorbeugung oder behandlung von neurodegenerativen störungen | |
| DE602005017373D1 (de) | Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten | |
| DE602006010544D1 (de) | Mit dem risiko von obesität und typ-2-diabetes assoziierter haplotyp des gens enpp1 (pc1) und anwendungen davon | |
| DE60126248D1 (de) | Verwendung von brustkrebs membranproteine für behandlung, prophylaxe und diagnose von brustkrebs | |
| ATE311476T1 (de) | Polymorphismen im gen für den humanen organischen anionentransporter c (oatp-c) | |
| EA200702212A1 (ru) | Способ лечения или профилактики разрушения кости или остеопороза | |
| ATE346597T1 (de) | Carbamate verbindungen zur behandlung oder verhutung von psychotischen krankheiten | |
| WO2007126823A3 (en) | Modified metallothioneins and methods for screening and treatment of diseases associated with oxidative stress | |
| DK1745295T3 (da) | Fremgangsmåder, sammensætninger og forbindelsesanalyser til hæmning af produktionen af amyloid beta-protein | |
| ATE506947T1 (de) | Kondensierte thiophene verbindungen und deren verwendung zur behandlung von chronischen schmerzen | |
| DE602005014778D1 (de) | Timp-2 als ziel/marker des versagens von beta-zellen | |
| ATE463562T1 (de) | Lp-pla2-aktivitätstest mit hohem durchsatz | |
| ATE549352T1 (de) | Verwendung sekretierter proteinprodukte zur prävention und behandlung von erkrankungen der bauchspeicheldrüse und/oder adipositas und/oder des metabolischen syndroms | |
| DE602005007471D1 (de) | Satraplatin zur behandlung von resistenten oder refrkatären tumoren | |
| ATE534751T1 (de) | Verwendung von prkx zur diagnose und therapie von alzheimer krankheit | |
| ATE443262T1 (de) | Molekulardiagnoseverfahren und behandlung von demenz mit lewy-körperchen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1378753 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |